Numb. Credit: Ten Thirty Nine from Flickr.
The pharmaceutical industry has in part withdrawn, either because they struggled to translate research into a viable drug or because of financial pressures." - —Barbara Sahakian Leading international academics are advocating for new approaches to drug development for mental health diseases. Their comment article depression, and schizophrenia. Professor Barbara Sahakian, of the Department of Psychiatry and MRC/Wellcome Trust Behavioural and Clinical Neuroscience Institute at the University of Cambridge, and Thomas Insel, Director of the National Institute of Mental Health in the United States, were leaders on the comment piece after a Royal Society meeting held to address the 'pharmacological impasse' concluded that the lack of viable new treatments 'calls for a fundamental change in nearly every aspect of translational research in mental health'. Despite nearly 40% of the population being affected by mental health issues, which includes everything from depression and dementia to anxiety and schizophrenia, the researchers say there is a crisis in the development of new treatments for these disorders. Professor Sahakian explains part of the problem, "The pharmaceutical industry has in part withdrawn, either because they struggled to translate research into a viable drug or because of financial pressures. Although some have remained, there are still insufficient resources being focused on diseases which affect a disproportionate percentage of the population." In the comment article, they cite genetics as providing fertile ground for drug exploration, highlighting the impact it has had on other medical treatments.
TO READ THIS ARTICLE, CREATE YOUR ACCOUNT
And extend your reading, free of charge and with no commitment.
